• Align Capital Partners-backed Premier Biotech acquired NexScreen and TransMed to expand its drug and alcohol testing solutions platform.
• NexScreen adds point-of-care diagnostics distribution across the US, Australia, and New Zealand, extending Premier’s geographic reach.
• TransMed brings an e-commerce platform and a broad drug-testing and lab-supplies catalog serving more than 1,000 direct customer accounts.
• The deals broaden Premier’s product portfolio and deepen relationships across healthcare, government, and workplace end markets.
• Premier has completed seven acquisitions since partnering with Align Capital Partners in November 2022.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Align Capital Partners LLC published the original content used to generate this news brief on June 18, 2026, and is solely responsible for the information contained therein.